FOR IMMEDIATE RELEASE …

                                             FOR IMMEDIATE RELEASE

   NextGen Sciences and Expression Pathology to provide protein biomarker discovery and
                                 measurement in tissue


Ann Arbor, MICHIGAN and Gaithersburg, MARYLAND, May 5, 2008 - NextGen Sciences, Inc (Ann Arbor, MI), a
provider of biomarker services, and Expression Pathology Inc. (Gaithersburg, MD), a leader in tissue protein analysis,
announced today that they have signed a commercial agreement to provide protein biomarker services in formalin-fixed
paraffin-embedded (FFPE) tissue samples. The new combined offering will provide researchers with an improved, mass
spectrometry based alternative to the commonly used immunohistochemistry method for identification and analysis of
tissue proteins, reducing drug development timelines and providing accurate and quantitative measurement of protein
biomarkers of disease progression, drug response and toxicity.


In addition to providing true quantitative protein analysis in FFPE tissue, which is not possible with current methods, the
new services are expected to save months in the drug development process. Immunohistochemistry is laborious and
often require several months for the production of an antibody against the protein of interest. However, the projects run
by NextGen and Expression Pathology take less time to complete and do not require antibodies for protein quantitation.


To access the services, customers can send their FFPE tissue samples to either NextGen or Expression Pathology.
Expression Pathology has developed innovative, proprietary techniques for microdissection, extraction and solubilization
of the protein content of FFPE tissue. Customer samples are processed using the Company's Liquid Tissue® MS Protein
Prep and DirectorTM laser micro-dissection technologies. Once extracted, the proteins are analyzed with NextGen's LC-
MS/MS technologies to identify and quantify protein levels from healthy versus diseased or treated versus untreated
samples. This workflow can be used at any stage of a project including biomarker discovery, biomarker assay
development and biomarker testing. For discovery, the deliverable is a list of candidate protein biomarkers identified and
quantified in each tissue sample. For biomarker testing, the deliverable is relative and/or absolute quantitation for the
client's targeted list of protein biomarkers. See notes to editor for more technical details


Dr. Mike Pisano, President of NextGen, said: "Our combined services will aid in the most challenging task of selecting the
appropriate biomarkers for specific drug development programs. This agreement extends our biomarkerexpressTM service
portfolio, and underlines our commitment to enable biopharma customers to select the best biomarkers for each Research
and Development program, and for use in personalized medicine."


Casey Eitner, President and CEO of Expression Pathology, commented: "These services provide our customers, for the
first time, accurate and quantitative measurement of protein expression levels in FFPE tissue, improving the effectiveness
and reducing time limes in drug development."


                                                        - ENDS -



Enquiries:

NextGen Sciences
Mike Pisano, President
+1 734 973 7914

College Hill
Lorna Cuddon, Katie Odgaard, Benjamyn Tan
+44 20 7457 2020
nextgen@collegehill.com

Expression Pathology
Peter Tunon, Vice President, Sales and Marketing
+1 (301) 977-3654
p.tunon@expressionpathology.com

Notes to Editors

NextGen
NextGen Group PLC (AIM: NGG) is a provider of biomarker services for pharmaceutical and biotech companies globally.
Using advanced techniques, such as Multiple Reaction Monitoring (MRM) mass spectrometry analysis, the Company is
developing a portfolio of robust assays for testing clinical samples for drug safety and efficacy, and the development of
personalised treatment for patients.

Headquartered in Ann Arbor, Michigan, NextGen's range of services, which include biomarker testing, discovery and assay
development, are employed by its customers as a key part of the biomarker-based drug and diagnostic development
process.

For more information visit www.nextgensciences.com

About Expression Pathology Inc.
Formalin-fixed and paraffin-embedded (FFPE) tissue samples are routinely collected and stored in medical treatment and
research facilities. They constitute a huge untapped resource for discovery, validation and accurate measurement of
biomarkers of disease progression and recurrence, drug response and toxicity. Expression Pathology's Liquid Tissue®
reagents and DirectorTM laser microdissection slides are opening new ways to extract valuable protein information from
FFPE tissue, and could provide the foundation for a new generation of clinical research and diagnostic tools.

For more information visit www.expressionpathology.com